Zacks Research Comments on Alkermes FY2027 Earnings

Alkermes plc (NASDAQ:ALKS - Free Report) - Stock analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Alkermes in a report issued on Wednesday, March 5th. Zacks Research analyst R. Department anticipates that the company will post earnings of $1.15 per share for the year. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share.

Alkermes (NASDAQ:ALKS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%.

A number of other research firms have also recently weighed in on ALKS. StockNews.com raised shares of Alkermes from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Mizuho boosted their target price on shares of Alkermes from $35.00 to $40.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. UBS Group upgraded Alkermes from a "sell" rating to a "neutral" rating and lifted their price target for the company from $21.00 to $38.00 in a report on Tuesday, March 4th. The Goldman Sachs Group boosted their price target on Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Alkermes in a research note on Tuesday, February 11th. They issued a "buy" rating and a $40.00 target price on the stock. Three research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $38.33.

Remove Ads

Alkermes Trading Up 2.6 %

Shares of Alkermes stock traded up $0.89 on Thursday, reaching $35.24. 1,863,917 shares of the stock were exchanged, compared to its average volume of 1,738,340. The business has a fifty day moving average price of $31.85 and a two-hundred day moving average price of $29.64. Alkermes has a 1-year low of $22.90 and a 1-year high of $36.45. The firm has a market capitalization of $5.73 billion, a PE ratio of 16.24, a PEG ratio of 2.20 and a beta of 0.62.

Institutional Trading of Alkermes

A number of institutional investors and hedge funds have recently modified their holdings of the business. RTW Investments LP boosted its stake in Alkermes by 13.6% during the 4th quarter. RTW Investments LP now owns 7,557,835 shares of the company's stock valued at $217,363,000 after purchasing an additional 903,802 shares during the period. Renaissance Technologies LLC raised its position in shares of Alkermes by 1.1% during the fourth quarter. Renaissance Technologies LLC now owns 5,478,728 shares of the company's stock worth $157,568,000 after purchasing an additional 57,697 shares during the period. American Century Companies Inc. lifted its stake in Alkermes by 6.5% during the fourth quarter. American Century Companies Inc. now owns 3,450,707 shares of the company's stock valued at $99,242,000 after buying an additional 209,740 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Alkermes by 4.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,019,508 shares of the company's stock worth $86,842,000 after purchasing an additional 128,701 shares during the period. Finally, Avoro Capital Advisors LLC acquired a new position in Alkermes during the fourth quarter valued at $70,462,000. 95.21% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Alkermes

In other news, EVP Craig C. Hopkinson sold 144,419 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the sale, the executive vice president now directly owns 57,875 shares in the company, valued at approximately $2,056,298.75. The trade was a 71.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.89% of the company's stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.